Ranibizumab Versus Aflibercept for CRVO in Young Patients.

• Status: Recruiting
• Trial end date: 2022-05-31
• Target enrollment: 0
• Participant gender: All

Summary

this study will compare the efficacy and safety of use either Ranibizumab and Aflibercept in treatment of macular edema resulting from non ischemic central retinal vein occlusion in patients younger than 5o years old

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Qena Faculty of medicine, South Valley University
• Treatments: Aflibercept; Ranibizumab

Criteria

Inclusion Criteria:

• patients younger than 50 years with macular edema due to non-ischemic CRVO

Exclusion Criteria: Other conditions that might affect the macula as

1. diabetic retinopathy, intraocular inflammation, age related macular degeneration, patients with solar or radiation retinopathy,

2. patients with ischemic type CRVO and patients who had recent intraocular surgery.

3. patients who had previous intravitreal injections, ophthalmic laser surgeries.

4. patients with dense cataracts whom fundus was difficult to scan.

5. Patients who were lost to follow up visits were also excluded